The EU Non-Hodgkin Lymphoma therapeutics market size stood at around USD XX million in 2019 and is projected to reach USD xx million by 2028, exhibiting a CAGR of xx% during the forecast period

Lymphoma is one of the most commonly occurring cases of lymphomas and hence is also one of the most commonly occurring cancers. If not treated effectively, it is potentially lethal and leads to a shorter life span of the individuals diagnosed. There are various clinical trials being conducted by market players for the development of new non-hodgkin lymphoma treatment, especially for the relapsed and refractory forms



Market Drivers

In Europe, the strong awareness of the symptoms and treatment of non-Hodgkin lymphomas and the launch of new therapeutics such as CAR T-cell therapies is expected to drive market growth. The primary drivers of this market of non-Hodgkin lymphoma treatment, are the current trends of higher prevalence of almost all types of non-Hodgkin lymphomas. Better and positive clinical outcomes often occur due to the administration of efficient and advanced non-Hodgkin lymphoma treatment products